NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction

Shida Yang; Xin Li; Wenchang Guan; Mingqin Qian; Zhicheng Yao; Xiaoxue Yin; Hongmei Zhao

doi:10.18632/oncotarget.20943

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction

Shida Yang, Xin Li, Wenchang Guan, Mingqin Qian, Zhicheng Yao, Xiaoxue Yin and Hongmei Zhao _

PDF | HTML | How to cite

Oncotarget. 2017; 8:83052-83062. https://doi.org/10.18632/oncotarget.20943

Metrics: PDF 1442 views | HTML 1895 views | ?

Abstract

Shida Yang1, Xin Li2, Wenchang Guan3, Mingqin Qian4, Zhicheng Yao5, Xiaoxue Yin1 and Hongmei Zhao1

1Department of Laboratory Medicine, The People’s Hospital of Liaoning Province, Shenyang, China

2Department of Anesthesia, The People’s Hospital of Liaoning Province, Shenyang, China

3Department of Gynaecology and Obstetrics, The People’s Hospital of Liaoning Province, Shenyang, China

4Department of Ultrasound Diagnosis, The People’s Hospital of Liaoning Province, Shenyang, China

5Department of Neurology, The People’s Hospital of Liaoning Province, Shenyang, China

Correspondence to:

Hongmei Zhao, email: [email protected]

Keywords: NVP-BKM120, PUMA, apoptosis, FoxO3a, colon cancer

Received: May 09, 2017 Accepted: July 26, 2017 Published: September 15, 2017

ABSTRACT

NVP-BKM120, a potent and highly selective PI3K inhibitor, is currently being investigated in phase I/II clinical trials. The mechanisms of action of NVP-BKM120 in colon cancer cells are unclear. In the present study, we investigated how NVP-BKM120 suppresses colon cancer cells growth and potentiates effects of other chemotherapeutic drugs. We found that NVP-BKM120 treatment enhance PUMA induction irrespective of p53 status through the FoxO3a pathway following AKT inhibition. Furthermore, PUMA is required for NVP-BKM120-induced apoptosis in colon cancer cells. In addition, NVP-BKM120 also synergized with 5-Fluorouracil or regorafenib to induce marked apoptosis via PUMA induction. Deficiency of PUMA suppressed apoptosis and antitumor effect of NVP-BKM120 in xenograft model. These results demonstrate a key role of PUMA in mediating the anticancer effects of NVP-BKM120 and suggest that PUMA could be used as an indicator of NVP-BKM120 sensitivity, and also have important implications for it clinical applications.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20943

Publication Alerts

Research Papers:

NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction

Abstract